These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 17693643)
1. The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma. Teng HW; Chen PM; Yang YH; Gau JP Jpn J Clin Oncol; 2007 Aug; 37(8):609-14. PubMed ID: 17693643 [TBL] [Abstract][Full Text] [Related]
2. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Perosa F; Minoia C; Favoino E; Prete M; Dammacco F Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035 [TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors affecting survival in multiple myeloma]. Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822 [TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)]. Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207 [TBL] [Abstract][Full Text] [Related]
5. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. Rossi F; Petrucci MT; Guffanti A; Marcheselli L; Rossi D; Callea V; Vincenzo F; De Muro M; Baraldi A; Villani O; Musto P; Bacigalupo A; Gaidano G; Avvisati G; Goldaniga M; Depaoli L; Baldini L Clin Cancer Res; 2009 Jul; 15(13):4439-45. PubMed ID: 19509142 [TBL] [Abstract][Full Text] [Related]
7. Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital. Chng WJ; Sum C; Kuperan P Singapore Med J; 2005 Sep; 46(9):450-6. PubMed ID: 16123828 [TBL] [Abstract][Full Text] [Related]
8. Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia. Pandey S; Post SR; Alapat DV; Smock KJ; Post GR Int J Lab Hematol; 2013 Aug; 35(4):421-7. PubMed ID: 23217011 [TBL] [Abstract][Full Text] [Related]
9. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Huang H; Li H; Li D Blood Coagul Fibrinolysis; 2015 Jul; 26(5):555-9. PubMed ID: 25828972 [TBL] [Abstract][Full Text] [Related]
10. Measurement of prothrombin time and activated partial thromboplastin time in citrated whole blood samples from clinically ill dogs following storage. Maunder CL; Costa M; Cue SM; Crawford EM; Papasouliotis K; Murphy KF J Small Anim Pract; 2012 Sep; 53(9):531-5. PubMed ID: 22860986 [TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Elice F; Fink L; Tricot G; Barlogie B; Zangari M Br J Haematol; 2006 Aug; 134(4):399-405. PubMed ID: 16882132 [TBL] [Abstract][Full Text] [Related]
12. [Prognostic Value of Prothrombin Time and Activated Partial Thromboplastin Time in Newly Diagnosed Patients with Multiple Myeloma]. Wang LJ; Han MR; Dong CX; Tian WW; Lu XY; Yang LH; Ma YP; Wang MF Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):805-810. PubMed ID: 38926971 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of drawing coagulation samples from heparinized arterial lines. Templin K; Shively M; Riley J Am J Crit Care; 1993 Jan; 2(1):88-95. PubMed ID: 8353585 [TBL] [Abstract][Full Text] [Related]
14. Acquired coagulopathy owing to parenteral cefamandole: renal failure as a predisposing factor. Chang JC Ann Clin Lab Sci; 1983; 13(5):418-24. PubMed ID: 6638932 [TBL] [Abstract][Full Text] [Related]
15. [Prolonged activated partial thromboplastin time, Quick's time, bleeding time. Diagnostic orientation]. Guillin MC Rev Prat; 1994 Sep; 44(14):1942-8. PubMed ID: 7939287 [No Abstract] [Full Text] [Related]
16. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system]. Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648 [TBL] [Abstract][Full Text] [Related]
17. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Braun PJ; Givens TB; Stead AG; Beck LR; Gooch SA; Swan RJ; Fischer TJ Thromb Haemost; 1997 Sep; 78(3):1079-87. PubMed ID: 9308757 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252 [TBL] [Abstract][Full Text] [Related]
19. Immunological methods in the diagnosis of monoclonal gammopathies. The prognostic impact of the immunological data. Baldea L; Cucuianu A; Cristea A Rom J Intern Med; 1999; 37(3):217-25. PubMed ID: 15532300 [TBL] [Abstract][Full Text] [Related]
20. Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. Matta GM; Battaglio S; Dibello C; Napoli P; Baldi C; Ciccone G; Coscia M; Boccadoro M; Massaia M Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5348-54. PubMed ID: 17875762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]